• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bearish Sentiment Across The Cannabis Space - Check Full Movers For June 25, 2024

    6/25/24 4:30:05 PM ET
    $CARA
    $CGC
    $GENE
    $MXC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CARA alert in real time by email

    GAINERS:

    • Global Hemp Group (OTC:GBHPF) shares closed up 29.87% at $0.03
    • Target Group (OTC:CBDY) shares closed up 15.79% at $0.00
    • Body and Mind (OTC:BMMJ) shares closed up 14.14% at $0.05
    • Kaya Holdings (OTC:KAYS) shares closed up 11.63% at $0.05
    • Rocky Mountain High (OTC:RMHB) shares closed up 11.33% at $0.02
    • Blueberries Medical (OTC:BBRRF) shares closed up 11.11% at $0.01
    • CLS Holdings USA (OTC:CLSH) shares closed up 9.45% at $0.05
    • MJ Holdings (OTC:MJNE) shares closed up 8.89% at $0.00
    • CV Sciences (OTC:CVSI) shares closed up 4.32% at $0.06
    • Genetic Technologies (NASDAQ:GENE) shares closed up 4.07% at $1.48
    • Mexco Energy (AMEX:MXC) shares closed up 3.47% at $11.34
    • AusCann Group Holdings (OTC:ACNNF) shares closed up 3.45% at $0.01

    LOSERS:

    • Elixinol Wellness (OTC:ELLXF) shares closed down 58.76% at $0.00
    • GSRX Industries (OTC:GSRX) shares closed down 50.00% at $0.0001
    • Zelira Therapeutics (OTC:ZLDAF) shares closed down 34.07% at $0.19
    • Pharmadrug (OTC:LMLLF) shares closed down 20.85% at $0.01
    • Leafbuyer Techs (OTC:LBUY) shares closed down 19.20% at $0.02
    • Maple Leaf Green World (OTC:MGWFF) shares closed down 17.97% at $0.02
    • Charlottes Web Holdings (OTC:CWBHF) shares closed down 8.93% at $0.15
    • Cannabix Technologies (OTC:BLOZF) shares closed down 7.82% at $0.31
    • Cara Therapeutics (NASDAQ:CARA) shares closed down 7.80% at $0.33
    • Canopy Gwth (NASDAQ:CGC) shares closed down 7.58% at $6.48
    • Cresco Labs (OTC:CRLBF) shares closed down 7.14% at $1.58
    • Nextleaf Solutions (OTC:OILFF) shares closed down 6.28% at $0.06
    • C21 Investments (OTC:CXXIF) shares closed down 4.80% at $0.27
    • Auxly Cannabis Group (OTC:CBWTF) shares closed down 3.78% at $0.02
    • Trulieve Cannabis (OTC:TCNNF) shares closed down 3.63% at $9.85
    • 22nd Century Group (NASDAQ:XXII) shares closed down 3.19% at $0.67
    • Cansortium (OTC:CNTMF) shares closed down 3.13% at $0.14

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARA
    $CGC
    $GENE
    $MXC

    CompanyDatePrice TargetRatingAnalyst
    Canopy Growth Corporation
    $CGC
    11/10/2025Sell → Hold
    The Benchmark Company
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Hold
    Needham
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Neutral
    H.C. Wainwright
    Canopy Growth Corporation
    $CGC
    4/4/2023Underperform → Mkt Perform
    Bernstein
    Cara Therapeutics Inc.
    $CARA
    3/8/2023$13.00 → $6.00Neutral → Underperform
    BofA Securities
    Canopy Growth Corporation
    $CGC
    11/2/2022$1.50Underperform
    Bernstein
    More analyst ratings

    $CARA
    $CGC
    $GENE
    $MXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc sold $9,951 worth of shares (9,376 units at $1.06), decreasing direct ownership by 1% to 802,992 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    2/12/26 7:53:43 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Yanofsky Theresa sold $11,790 worth of shares (10,434 units at $1.13), decreasing direct ownership by 14% to 63,518 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    1/2/26 4:38:18 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Lazzarato David Angelo sold $17,758 worth of shares (15,715 units at $1.13), decreasing direct ownership by 15% to 87,672 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    1/2/26 4:37:09 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $GENE
    $MXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces MTL Cannabis Shareholder Approval of Acquisition

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce that shareholders of MTL Cannabis Corp. ("MTL Cannabis" or "MTL") have voted to approve the Company's previously announced acquisition of MTL (the "Transaction") at a special meeting of shareholders of MTL (the "MTL Shareholders") held February 17, 2026. The plan of arrangement with Canopy Growth received overwhelming support from MTL Shareholders, with (i) 99.97% of all shares of MTL (the "MTL Shares") cast in favour of the special resolution approving the Transaction, and (ii) 99.80% of MTL Shares, excluding votes attached to MTL Shares required to be excluded pursuant to Multilat

    2/18/26 7:56:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Mexco Energy Corporation Reports Financial Results for Third Quarter

    MIDLAND, TX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE:MXC) today reported net income of $615,702, or $0.30 per diluted share, for the nine months ending December 31, 2025. For the third quarter of fiscal 2026, the Company reported net income of $50,245, or $0.02 per diluted share, a decrease of 89% when compared to $469,133, or $0.22 per diluted share, for the prior year quarter. This decrease is primarily due to the decline in oil prices. Operating revenues in the third quarter of fiscal 2026 were $1,383,887. For the nine months ended December 31, 2025, operating revenues were $4,932,806, a decrease of 8% when compared to the first nine months of fiscal 2025. Thi

    2/10/26 5:00:00 PM ET
    $MXC
    Oil & Gas Production
    Energy

    $CARA
    $CGC
    $GENE
    $MXC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canopy Growth upgraded by The Benchmark Company

    The Benchmark Company upgraded Canopy Growth from Sell to Hold

    11/10/25 8:33:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Cara Therapeutics downgraded by Stifel with a new price target

    Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously

    6/13/24 7:05:24 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously

    6/13/24 7:05:04 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CGC
    $GENE
    $MXC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $GENE
    $MXC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CGC
    $GENE
    $MXC
    SEC Filings

    View All

    22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    2/20/26 4:15:28 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by Canopy Growth Corporation

    EFFECT - Canopy Growth Corp (0001737927) (Filer)

    2/17/26 12:15:34 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Canopy Growth Corporation

    424B3 - Canopy Growth Corp (0001737927) (Filer)

    2/13/26 4:08:07 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $GENE
    $MXC
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth to Acquire MTL Cannabis; Transaction Expected to Create Canada's Leading Medical Cannabis Business and Enhance Capacity to Serve Growing International Demand

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Highly accretive business combination expected to generate significant run-rate synergies of approximately $10 million within 18 months Strengthens Canopy Growth's presence in Québec with an opportunity to expand national distribution of MTL's high-quality, budtender-recommended product portfolio2 MTL's core management team is expected to join Canopy Growth to drive cultivation excellence and enhance the Company's p

    12/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, is pleased to announce today the voting results from its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 7, 2025 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of t

    10/14/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Appoints Tom Stewart as Chief Financial Officer

    Appointment finalizes CFO transition and reinforces Canopy Growth's focus on operational discipline, financial stability, and long-term value creation Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced that Tom Stewart has been appointed Chief Financial Officer, effective immediately. Mr. Stewart's appointment supports the continued execution of Canopy Growth's fiscal year 2026 strategy, which is marked by structural efficiency, operational and commercial focus, and disciplined capital allocation and cost management. With significant progres

    9/17/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $GENE
    $MXC
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Mexco Energy Corporation Reports Financial Results for Third Quarter

    MIDLAND, TX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE:MXC) today reported net income of $615,702, or $0.30 per diluted share, for the nine months ending December 31, 2025. For the third quarter of fiscal 2026, the Company reported net income of $50,245, or $0.02 per diluted share, a decrease of 89% when compared to $469,133, or $0.22 per diluted share, for the prior year quarter. This decrease is primarily due to the decline in oil prices. Operating revenues in the third quarter of fiscal 2026 were $1,383,887. For the nine months ended December 31, 2025, operating revenues were $4,932,806, a decrease of 8% when compared to the first nine months of fiscal 2025. Thi

    2/10/26 5:00:00 PM ET
    $MXC
    Oil & Gas Production
    Energy

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $GENE
    $MXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Cara Therapeutics Inc.

    SC 13D - Cara Therapeutics, Inc. (0001346830) (Subject)

    10/30/24 4:21:50 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care